Horizon Discovery


Horizon Discovery logo

Horizon Discovery is a revenue-generating life science group supplying research tools to organizations engaged in translational genomics research and the development of personalized medicines. Horizon has a diverse and international customer base of over 1,200 organizations across more than 50 countries, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers. The Group supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015.

Horizon's core capabilities are built around its proprietary translational genomics platform, a high-precision and flexible suite of gene editing tools able to alter almost any endogenous gene sequence of human or mammalian cell-lines. Horizon offers over 20,000 catalogue products, almost all of which are based on the application of gene editing to generate cell lines that accurately model the disease-causing mutations found in genetically based diseases. These ‘patients-in-a-test-tube’ are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.

Contact Horizon Discovery via their website


News archive

25/09/2017   Horizon Discovery introduces OncoSpan Reference Standard...more
18/09/2017   Horizon Discovery announces launch of Genome-Wide Screening Services...more
01/08/2017   Horizon Discovery announces release of CHO genome sequence at EMBL-EBI...more
07/07/2017   Sphere Fluidics, Horizon Discovery and partners win $1.25m Innovate UK grant...more
13/07/2017   Horizon Discovery comments on UK Chief Medical Officer’s Generation Genome report ...more
05/07/2017   Horizon Discovery Takes Exclusive License for Gene Editing Technology Platform...more
16/06/2017   Horizon Discovery’s RNA reference standards endorsed in White Paper...more
14/06/2017   Horizon Discovery Announces Progress for Contract Service and Therapeutic Programme...more
01/06/2017   ATUM and Horizon Discovery Announce Collaboration and Technology Cross-License...more
26/05/2017   Horizon Discovery introduces four BRAF resistant melanoma PDX models...more
22/05/2017   Horizon Discovery Announces New Gene Editing Technology Platform for R&D...more
09/05/2017   Horizon Discovery provides Immuno-Oncology platform update...more
11/04/2017   Horizon Discovery links Acquisition of Agalimmune with Avvinity Therapeutics potential...more
20/03/2017   Horizon Discovery(s knockout rat models paving the way for Autism drugs...more
14/03/2017   Horizon Discovery Enters into Agreement with Leading Global Molecular Diagnostics Provider...more
08/03/2017   Horizon Discovery enters into R&D and licensing partnership with Amplycell S.A....more
16/01/2017   Horizon announces extension of key CRISPR license and grant-funded research...more
13/01/2017   International Trade Minister Greg Hands visits Horizon Discovery ...more

20/12/2016   Horizon Discovery Announces Progress Update on Cell Line Catalogue Business...more
15/12/2016   Sygnature Discovery releases publication highlighting biomarker validation...more
14/12/2016   Horizon Discovery Announces Progress Update on its Biomanufacturing Business...more
08/12/2016   Horizon Discovery Announces Progress Update on its Genetic Screening Platform...more
01/12/2016   Horizon Discovery product included in Top 10 Innovations list - fourth year running...more
18/11/2016   Horizon Discovery Ranked UK's 41st Fastest Growing Technology Company...more
17/11/2016   Horizon Discovery Partners with Sophia Genetics for Oncology Applications...more
16/11/2016   Horizon Discovery Enters Chinese Clinical Diagnostics Market...more
01/11/2016   Horizon Discovery And CareDx Enter Into OEM Agreement...more
01/11/2016   Horizon Discovery Announces High-throughput Molecular Screening Platform Update...more
19/10/2016   Horizon Discovery Signs Licensing Agreement for Biomanufacturing Cell Lines...more
13/09/2016   Horizon Discovery Licenses Cell Lines To CPI and NIBRT...more
01/09/2016   Horizon Discovery and Ventana Medical Systems Sign Co-Development Agreement...more
20/07/2016   Horizon Discovery Takes Exclusive Xenograft Models License...more
01/06/2016   Horizon Discovery joins the BioPartner programme...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code